Michael Metschl is a partner and the head of therapeutics at Braidwell, a role they have held since 2022. Prior to this, Michael worked as a biotech investor during a non-compete period from 2021 to 2022, and was a biotech analyst at Citadel Global Equities from 2020 to 2021. They began their career as an investment banking analyst at Citi from 2008 to 2010 and spent a decade as a therapeutics research analyst at OrbiMed from 2010 to 2020. Michael is currently pursuing a Bachelor of Business Administration in Finance, with a Chinese co-major, at the University of Notre Dame, where they are expected to graduate summa cum laude.
This person is not in the org chart
This person is not in any teams
This person is not in any offices